<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Procarbazine <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> is an oral <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> with activity against <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is most commonly used in the treatment of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> fell out of favor with the advent of CHOP </plain></SENT>
<SENT sid="3" pm="."><plain>We report two patients with relapsed and/or refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that achieved a complete and durable remission with a prolonged course of daily procarbazine </plain></SENT>
</text></document>